Safety of magnetic resonance contrast agents

Magnetic Resonance Procedures: Health Effects and Safety

Volumn , Issue , 2000, Pages 241-259

  Runge, Val M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907570453     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Vogl, T.J., Pegios, W., McMahon, C., et al, Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers, Am. J. Roentgenol., 158(4):887-1892, 1992.
2. Spinazzi, A., Lorusso, V., Pirovano, G., and Kirchin, M., Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers, Acad. Radiol., 6(5):282-291, 1999.
3. Staks, T., Schuhmann-Giampieri, G., Frenzel, T., et al., Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers, Invest. Radiol., 29(7):709-715, 1994.
4. Hartmann, M., Forsting, M., Jansen, O., et al, Does the administration of a high dose of a paramagnetic contrast medium (Gadovist) improve the diagnostic value of magnetic resonance tomography in glioblastomas?, Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb Verfahr., 164(2):119-125, 1996.
5. Small, W.C., DeSimone-Macchi, D., Parker, J.R., et al., A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis, J. Magn. Reson. Imaging., 10(1):15-24, 1999.
6. Hamm, B., Staks, T., Muhler, A., et al., Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging, Radiology., 195(3):785-792, 1995.
7. Reimer, P., Rummeny, E.J., Shamsi, K., et al., Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence, Radiology., 199(1):177-183, 1996.
8. Giovagnoni, A. and Paci, E., Liver. III: gadolinium-based hepatobiliary contrast agents (Gd-EOBDTPA and Gd-BOPTA/Dimeg), Magn. Reson. Imaging Clin. North Am., 4(1):61-72, 1996.
9. Ni, Y. and Marchal, G, Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments, Top. Magn. Reson. Imaging., 9(3):183-195, 1998.
10. Hamm, B., Staks, T., Taupitz, M., et al., Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide, J. Magn. Reson. Imaging., 4(5):659-668, 1994.
11. Laniado, M., Kopp, A.F, Current status of the clinical development of MR contrast media, Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb Verfahr., 167(6):541-550, 1997.
12. Chen, F., Ward, J., and Robinson, P.J., MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superparamagnetic iron oxide agents, Magn, Reson. Imaging., 17(4):549-556, 1999.
13. Runge, V.M., Schoerner, W., Niendorf, H.P., et al, Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging, Magn, Reson. Imaging., 3(1):27-35, 1985.
14. Goldstein, H.A., Kashanian, F.K., Blumetti, R.F., et al, Safety assessment of gadopentetate dimeglumine in U.S. clinical trials, Radiology., 174(1):17-23, 1990.
15. Nelson, K.L., Gifford, L.M., Lauber-Huber, C., et al, Clinical safety of gadopentetate dimeglumine, Radiology., 196(2):439-443, 1995.
16. Niendorf, H.P., Alhassan, A., Geens, V.R., and Clauss, W, Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications, Invest. Radiol., 29 (Suppl. 2):S179-S182, 1994.
17. Runge, V.M., Bradley, W.G., Brant-Zawadzki, M.N., et al, Clinical safety and efficacy of gadoteridol:a study in 411 patients with suspected intracranial and spinal disease, Radiology., 181(3):701-709, 1991.
18. Seiderer, M., Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology. A European perspective, Invest. Radiol., 27 (Suppl. 1):S33-S38, 1992.
19. Olukotun, A.Y., Parker, J.R., Meeks, M.J., et al, Safety of gadoteridol injection: U.S. clinical trial experience, J. Magn. Reson. Imaging., 5(1):17-25, 1995.
20. Yuh, W.T., Fisher, D.J., Runge, V.M., et al., Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases, Am. J. Neuroradiol., 15(6):1037-1051, 1994.
21. Runge, V.M. and Parker, J.R, Worldwide clinical safety assessment of gadoteridol injection: an update, Eur. Radiol., 7(Suppl. 5):243-245, 1997.
22. Tweedle, M.F., The ProHance story: the making of a novel MRI contrast agent, Eur. Radiol., 7(Suppl. 5):225-230, 1997.
23. Sze, G., Brant-Zawadzki, M., Haughton, V.M., et al, Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine, Radiology., 181(3):693-699, 1991.
24. Brugieres, P., Gaston, A., Degryse, H.R., et al, Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA), Neuroradiology., 36(1):27-30, 1994.
25. Oudkerk, M., Sijens, P.E., Van Beek, E.J., and Kuijpers, T.J, Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system, Invest. Radiol., 30(2):75-78, 1995.
26. Tweedle, M.F, Nonionic or neutral?, Radiology, 178(3):891, 1991.
27. McAlister, W.H., McAlister, V.I., and Kissane, J.M, The effect of Gd-dimeglumine on subcutaneous tissues: a study with rats, Am. J. Neuroradiol., 11(2):325-327,1990.
28. Cohan, R.H., Leder, R.A., Herzberg, A.J., et al, Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat, Invest. Radiol., 26(3):224-226, 1991.
29. Vehmas, T. and Markkola, A.T., Gd-DTPA as an alternative contrast agent in conventional and interventional radiology, Acta Radiol., 39(3):223-226, 1998.
30. Tweedle, M.F., Hagan, J.J., Kumar, K., et al, Reaction of gadolinium chelates with endogenously available ions, Magn, Reson. Imaging., 9(3):409-415, 1991.
31. Puttagunta, N.R., Gibby, W.A., and Puttagunta, V.L, Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media, Invest. Radiol., 31(10):619-624, 1996.
32. Wedeking, P., Kumar, K., and Tweedle, M.F, Dissociation of gadolinium chelates in mice: relationship to chemical characteristics, Magn, Reson. Imaging., 10(4):641-648, 1992.
33. Tweedle, M.F., Wedeking, P., and Kumar, K, Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats, Invest. Radiol., 30(6):372-380, 1995.
34. Puttagunta, N.R., Gibby, W.A., and Smith, G.T, Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents, Invest. Radiol., 31(12):739-742, 1996.
35. Corot, C., Idee, J.M., Hentsch, A.M., et al., Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme, J. Magn. Reson. Imaging., 8(3):695-702, 1998.
36. Toft, K.G., Hustvedt, S.O., Grant, D., et al, Metabolism and pharmacokinetics of MnDPDP in man, Acta Radiol., 38(4, Pt. 2):677-689, 1997.
37. Toft, K.G., Kindberg, G.M., and Skotland, T, Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood, J. Pharm. Biomed. Anal., 15(7):983-988, 1997.
38. Toft, K.G., Hustvedt, S.O., Grant, D., et al, Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs, Eur. J. Drug Metab. Pharmacokinet., 22(1):65-72, 1997.
39. Weiss, K.L, Severe anaphylactoid reaction after i.v. Gd-DTPA, Magn, Reson. Imaging., 8(6):817-818, 1990.
40. Lufkin, R.B, Severe anaphylactoid reaction to Gd-DTPA, Radiology, 176(3):879, 1990.
41. Tishler, S. and Hoffman, J.C., Jr, Anaphylactoid reactions to i.v. gadopentetate dimeglumine, Am. J. Neuroradiol., 11(6):1167, 1990.
42. Salonen, O.L, Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration, J. Comput. Assist. Tomogr., 14(6):912-913, 1990.
43. Tardy, B., Guy, C., Barral, G., et al, Anaphylactic shock induced by intravenous gadopentetate dimeglumine, Lancet, 339(8791):494, 1992.
44. Katoh, A., Kishikawa, T., Kudo, S., et al, Anaphylactoid reaction after intravenous administration of Gd-DTPA, Nippon Igaku Hoshasen Gakkai Zasshi., 53(8):973-975, 1993.
45. Nomura, M., Takeshita, G., Katada, K., et al., A case of anaphylactic shock following the administration of Gd-DTPA, Nippon Igaku Hoshasen Gakkai Zasshi., 53(12):1387-1391, 1993.
46. Jordan, R.M. and Mintz, R.D, Fatal reaction to gadopentetate dimeglumine, Am. J. Roentgenol., 164(3):743-744, 1995.
47. Shellock, F.G., Hahn, H.P., Mink, J.H., and Itskovich, E, Adverse reaction to intravenous gadoteridol, Radiology., 189(1):151-152, 1993.
48. Witte, R.J. and Anzai, L.L, Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine, Am. J. Neuroradiol., 15(3):523-524, 1994.
49. Meuli, R.A. and Maeder, P, Life-threatening anaphylactoid reaction after iv injection of gadoterate meglumine, Am. J. Roentgenol., 166(3):729, 1996.
50. Carr, J.J, Magnetic resonance contrast agents for neuroimaging. Safety issues, Neuroimaging Clin. North Am., 4(1):43-54, 1994.
51. Niendorf, H.P., Dinger, J.C., Haustein, J., et al, Tolerance data of Gd-DTPA: a review, Eur. J. Radiol., 13(1):15-20, 1991.
52. Murphy, K.J., Brunberg, J.A., and Cohan, R.H, Adverse reactions to gadolinium contrast media: a review of 36 cases, Am. J. Roentgenol., 167(4):847-849, 1996.
53. Caro, J.J., Trindade, E., and McGregor, M, The cost-effectiveness of replacing high-osmolality with low-osmolality contrast media, Am. J. Roentgenol., 159(4):869-874, 1992.
54. Hustvedt, S.O., Grant, D., Southon, T.E., and Zech, K, Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration, Acta Radiol., 38(4, Pt. 2):690-699, 1997.
55. Lim, K.O., Stark, D.D., Leese, P.T., et al., Hepatobiliary MR imaging: first human experience with MnDPDP, Radiology., 178(1):79-82, 1991.
56. Kopp, A.F., Laniado, M., Aicher, K.P., et al., Manganese DPDP as a contrast medium for MR tomography of focal liver lesions. Tolerance and image quality in 20 patients, Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb Verfahr., 157(6):539-547, 1992.
57. Rummeny, E., Ehrenheim, C., Gehl, H.B., et al., Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients, Invest. Radiol., 26(Suppl. 1):S142-S145, 1991.
58. Aicher, K.P., Laniado, M., Kopp, A.F., et al., Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients, J. Magn. Reson. Imaging., 3(5):731-737, 1993.
59. Toft, K.G., Friisk, G.A., and Skotland, T, Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: detection and quantitation of the parent compound MnDPDP and metabolites in human plasma by high performance liquid chromatography, J. Pharm. Biomed. Anal., 15(7):973-981, 1997.
60. Wang, C., Ahlstrom, H., Ekholm, S., et al, Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study, Acta Radiol., 38(4, Pt. 2):643-649, 1997.
61. Torres, C.G., Lundby, B., Sterud, A.T., et al., MnDPDP for MR imaging of the liver. Results from the European phase III studies, Acta Radiol., 38(4, Pt. 2):631-637, 1997.
62. Mayo-Smith, W.W., Schima, W., Saini, S., et al, Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium, Am. J. Roentgenol., 170(3):649-652, 1998.
63. Wang, C., Johansson, L., Western, A., et al, Sequence optimization in mangafodipir trisodiumenhanced liver and pancreas MRI, J. Magn. Reson. Imaging., 9(2):280-284, 1999.
64. Ni, Y., Petre, C., Bosmans, H., et al, Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2, Acta Radiol., 38(4, Pt. 2):700-707, 1997.
65. Schima, W., Petersein, J., Hahn, P.F., et al., Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir, J. Magn. Reson. Imaging., 7(1):130-135, 1997.
66. Laniado, M. and Chachuat, A, The endorem tolerance profile, Radiologe, 35(11, Suppl. 2):S266-S270, 1995.
67. Stark, D.D., Weissleder, R., Elizondo, G., et al, Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver, Radiology., 168(2):297-301, 1988.
68. Yoshikawa, K., Sasaki, Y., Ogawa, N., Sakuma, S, Clinical application of AMI-25 (superparamagnetic iron oxide) for the MR imaging of hepatic tumors: a multicenter clinical phase III study, Nippon Igaku Hoshasen Gakkai Zasshi., 54(2):137-153, 1994.
69. Ros, P.R., Freeny, P.C., Harms, S.E., et al., Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions, Radiology., 196(2):481-488, 1995.
70. Ferrucci, J.T. and Stark, D.D, Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years, Am. J. Roentgenol., 155(5):943-950, 1990.
71. Rofsky, N.M., Weinreb, J.C., Bosniak, M.A., et al, Renal lesion characterization with gadoliniumenhanced MR imaging: efficacy and safety in patients with renal insufficiency, Radiology., 180(1):85-89, 1991.
72. Rominger, M.B., Kenney, P.J., Morgan, D.E., et al., Gadolinium-enhanced MR imaging of renal masses, Radiographics., 12(6):1097-1116, 1992.
73. Terens, W.L., Gluck, R., Golimbu, M., and Rofsky, N.M, Use of gadolinium-DTPA-enhanced MRI to characterize renal mass in patient with renal insufficiency, Urology., 40(2):152-154, 1992.
74. Brown, E.D. and Semelka, R.C, Magnetic resonance imaging of the adrenal gland and kidney, Top. Magn. Reson. Imaging., 7(2):90-101, 1995.
75. Yamashita, Y., Miyazaki, T., Hatanaka, Y., and Takahashi, M., Dynamic MRI of small renal cell carcinoma, J. Comput. Assist. Tomogr., 19(5):759-765, 1995.
76. Kaufman, J.A., Geller, S.C., and Waltman, A.C, Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures, Radiology., 198(2):579-581, 1996.
77. Ghantous, V.E., Eisen, T.D., Sherman, A.H., and Finkelstein, F.O, Evaluating patients with renal failure for renal artery stenosis with gadolinium-enhanced magnetic resonance angiography, Am. J. Kidney Dis., 33(1):36-42, 1999.
78. Cambria, R.P., Kaufman, J.L., Brewster, D.C., et al, Surgical renal artery reconstruction without contrast arteriography: the role of clinical profiling and magnetic resonance angiography, J. Vasc. Surg., 29(6):1012-1021, 1999.
79. Schuhmann-Giampieri, G. and Krestin, G, Pharmacokinetics of Gd-DTPA in patients with chronic renal failure, Invest. Radiol., 26(11):975-979, 1991.
80. Haustein, J., Niendorf, H.P., Krestin, G., et al, Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure, Invest. Radiol., 27(2):153-156, 1992.
81. Bellin, M.F., Deray, G., Assogba, U., et al., Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure, Magn, Reson. Imaging., 10(1):115-118, 1992.
82. Dorsam, J., Knopp, M.V., Schad, L., et al, Elimination of gadolinium-DTPA by peritoneal dialysis, Nephrol. Dial. Transplant., 10(7):1228-1230, 1995.
83. Choyke, P.L., Girton, M.E., Vaughan, E.M., et al, Clearance of gadolinium chelates by hemodialysis:an in vitro study, J. Magn. Reson. Imaging., 5(4):470-472, 1995.
84. Niendorf, E.R., Santyr, G.E., Brazy, P.C., and Grist, T.M, Measurement of Gd-DTPA dialysis clearance rates by using a look-locker imaging technique, Magn. Reson. Med., 36(4):571-578, 1996.
85. Arsenault, T.M., King, B.F., Marsh, J.W., Jr., et al, Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience, Mayo Clin. Proc., 71(12):1150-1154, 1996.
86. Yoshikawa, K. and Davies, A, Safety of ProHance in special populations, Eur. Radiol., 7(Suppl.5):246-250, 1997.
87. Joffe, P., Thomsen, H.S., and Meusel, M, Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis, Acad. Radiol., 5(7):491-502, 1998.
88. Hammer, F.D., Goffette, P.P., Malaise, J., and Mathurin, P, Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography, Eur. Radiol., 9(1):128-136, 1999.
89. Gerscovich, E.O., McGahan, J.P., Buonocore, M.H., et al, The rediscovery of infant feeding formula with magnetic resonance imaging, Pediatr. Radiol, 20:147-151, 1990.
90. King, C.P.L., Tart, R.P., Fitzsimmons, J.R., et al. Barium sulfate suspension as a negative oral MRI contrast agent: in vitro and human optimization studies, Magn, Reson. Imaging, 9:141-150, 1991.
91. Marti-Bonmati, L., Vilar, J., Paniagua, J.C., and Talens, A, High density barium sulphate as an MRI oral contrast, Magn, Reson. Imaging, 19:259-261, 1991.
92. Haldemann Heusler, R.C., Wight, E., and Marincek, B, Oral superparamagnetic contrast agent (ferumoxsil):tolerance and efficacy in MR imaging of gynecologic diseases, J. Magn. Reson. Imaging., 5(4):385-391, 1995.
93. Scheidler, J., Heuck, A.F., Meier, W., and Reiser, M.F., MRI of pelvic masses: efficacy of the rectal superparamagnetic contrast agent Ferumoxsil, J. Magn. Reson. Imaging., 7(6):1027-1032, 1997.
94. Hirohashi, S., Uchida, H., Yoshikawa, K., et al, Large scale clinical evaluation of bowel contrast agent containing ferric ammonium citrate in MRI, Magn, Reson. Imaging., 12(6):837-846, 1994.
95. Patten, R.M., Lo, S.K., Phillips, J.J., et al, Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials, Radiology., 189(1):277-283, 1993.
96. Bernardino, M.E., Weinreb, J.C., Mitchell, D.G., et al, Safety and optimum concentration of a manganese chloride-based oral MR contrast agent, J. Magn. Reson. Imaging., 4(6):872-876, 1994.
97. Laniado, M., Kornmesser, W., Hamm, B., et al., MR imaging of the gastrointestinal tract: value of Gd-DTPA, Am. J. Roentgenol, 150:817-821, 1988.
98. Kaminsky, S., Laniado, M., Gogoll, M., et al, Gadopentetate dimeglumine as a bowel contrast agent:safety and efficacy, Radiology, 178:503-508, 1991.
99. Claussen, C., Kornmesser, W., Laniado, M., et al, Oral contrast media for magnetic resonance tomography of the abdomen: III. Initial patient research with gadolinium DTPA, Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb Verfahr., 148:683-689, 1988.
100. Krahe, T., Dolken, W., Lackner, K., et al., Gadolinium DTPA as an oral contrast medium for MR tomography of the abdomen, Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb Verfahr., 153:167-173, 1990.